Incyte Stock - Jefferies nudges target higher after recent gains
Published on 06/18/2026 at 18:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:35 CET. Details in the imprint.
Incyte (US45337C1027) sees fresh analyst attention this week. Jefferies has raised its price target while reiterating a Hold rating, according to a recent update circulated via MarketScreener. Jefferies update reported by MarketScreener
All news and data on Incyte stock
Track analyst moves, fundamentals and price data for Incyte in one place on ad-hoc-news.de and compare them with the company’s own investor updates.
Jefferies trims discount, stays cautious
Jefferies now sees fair value for Incyte shares at $100, up from $94 previously, and keeps its Hold recommendation unchanged. MarketScreener summary of the Jefferies move That implies only limited upside versus the recent close just below $99.
The updated target comes as Incyte stock has delivered a solid double-digit gain over the past year, supported by a resilient revenue base in oncology and dermatology. The muted rating stance underlines that Jefferies sees the current valuation as broadly fair.
Technical picture on Thursday
On a closing basis, Incyte shares last changed hands at $98.99 on Nasdaq on 06/17/2026, with a modest 0.76% decline on the day. TradingKey quote overview for Incyte Pre-market indications on 06/18/2026 pointed slightly lower again.
At this level, the stock is not far from its recent 52-week highs, leaving the chart in reasonably constructive shape. Against this backdrop, investors are watching whether the shares can consolidate above the mid-$90s band, where trading activity has been dense in recent weeks.
The product engine behind Incyte
Incyte generates most of its revenue from specialty medicines in oncology and inflammation, led by Jakafi (ruxolitinib) for myelofibrosis and polycythemia vera. The company also earns royalty streams and collaboration income from partners on various targeted therapies.
Where the stock trades today
The shares of Incyte (US45337C1027) trade on Nasdaq at $98.99 as of 06/17/2026, 16:00 ET.
Key facts on Incyte stock
- Company: Incyte Corp.
- ISIN: US45337C1027
- WKN: 896133
- Ticker: INCY
- Venue: Nasdaq
- Price (as of 06/17/2026, 16:00 ET): 98.99 USD
- Market cap: 19.78 billion USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
